(R)-3'-((2-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-[1,1'-biphenyl]-3-carboxylic acid
CAS: 451470-34-1
Ref. 3D-BTA47034
1mg | A consultar | ||
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar |
Información del producto
- 3'-((2-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-(1,1'-biphenyl)-3-carboxylic acid
- Gw 427353b
- Solabegron hydrochloride
- [1,1′-Biphenyl]-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-, hydrochloride (1:1)
- [1,1′-Biphenyl]-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-, monohydrochloride
(R)-3'-((2-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-[1,1'-biphenyl]-3-carboxylic acid (Tolterodine tartrate) is a drug that is used to treat various types of urinary incontinence. It acts as an antimuscarinic by binding to the muscarinic receptors in the detrusor muscle and bladder wall, thereby decreasing involuntary contractions. Tolterodine tartrate has shown clinical response rates of up to 80% in patients with overactive bladder. It has been approved for use in adults and children who are at least 6 years old. Clinical trials have shown that this drug can also be used to reduce symptoms of urge incontinence and mixed incontinence. The pharmacological treatment is usually started with a low dose, which is gradually increased until it reaches the desired effect.
Propiedades químicas
Consulta técnica sobre: 3D-BTA47034 (R)-3'-((2-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)ethyl)amino)-[1,1'-biphenyl]-3-carboxylic acid
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.